About Xenikos
Xenikos is a company based in Nijmegen (Netherlands) founded in 2009.. Xenikos has raised $81.99 million across 5 funding rounds from investors including Rijksdienst voor Ondernemend Nederland, RA Capital and Oost NL. Xenikos offers products and services including T-Guard. Xenikos operates in a competitive market with competitors including Alexion, argenx, BigHat, GigaGen and Kodiak Sciences, among others.
- Headquarter Nijmegen, Netherlands
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Xenikos Us Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$81.99 M (USD)
in 5 rounds
-
Latest Funding Round
$2.48 M (USD), Grant
Oct 05, 2022
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Xenikos
Xenikos offers a comprehensive portfolio of products and services, including T-Guard. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Therapeutic tool to reset immune system for T-cell diseases.
Unlock access to complete
Unlock access to complete
Leadership Team
2 people
CMC Team
1 people
Chairman Team
1 people
Product Management Team
1 people
Controller Team
1 people
Unlock access to complete
Funding Insights of Xenikos
Xenikos has successfully raised a total of $81.99M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $2.48 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Grant — $2.5M
-
First Round
First Round
(19 Jun 2012)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2022 | Amount | Grant - Xenikos | Valuation |
investors |
|
| Sep, 2021 | Amount | Series C - Xenikos | Valuation | Veloxis | |
| May, 2018 | Amount | Series B - Xenikos | Valuation | Medicxi , RA Capital Management |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Xenikos
Xenikos has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Rijksdienst voor Ondernemend Nederland, RA Capital and Oost NL. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Founded Year | Domain | Location | |
|
Early-stage life science focused VC firm investing in geographies such as Europe and the US
|
Founded Year | Domain | Location | |
|
Sector-agnostic VC firm investing in geographies such as the Netherlands
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Xenikos
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Xenikos
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Xenikos Comparisons
Competitors of Xenikos
Xenikos operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alexion, argenx, BigHat, GigaGen and Kodiak Sciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for rare and devastating diseases are developed by Alexion.
|
|
| domain | founded_year | HQ Location |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| domain | founded_year | HQ Location |
Antibody therapies are developed through machine learning and synthetic biology.
|
|
| domain | founded_year | HQ Location |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| domain | founded_year | HQ Location |
Therapeutics for retinal diseases are developed by the company.
|
|
| domain | founded_year | HQ Location |
Developer of monoclonal antibodies against infectious diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Xenikos
Frequently Asked Questions about Xenikos
When was Xenikos founded?
Xenikos was founded in 2009 and raised its 1st funding round 3 years after it was founded.
Where is Xenikos located?
Xenikos is headquartered in Nijmegen, Netherlands. It is registered at Nijmegen, Gelderland, Netherlands.
Is Xenikos a funded company?
Xenikos is a funded company, having raised a total of $81.99M across 5 funding rounds to date. The company's 1st funding round was a Series B of $30M, raised on Jun 19, 2012.
What does Xenikos do?
Developer of toxin-loaded antibodies for T-cell mediated diseases. Based on the action of conjugated antibodies, it has developed its lead candidate T-Guard, a combination of two toxin-loaded anti-T-cell antibodies that can reset the bodys immune system in T-cell mediated diseases, such as Graft-versus-host disease (GVHD).
Who are the top competitors of Xenikos?
Xenikos's top competitors include argenx, GigaGen and Kodiak Sciences.
What products or services does Xenikos offer?
Xenikos offers T-Guard.
Who are Xenikos's investors?
Xenikos has 7 investors. Key investors include Rijksdienst voor Ondernemend Nederland, RA Capital, Oost NL, Sanquin, and Veloxis.